SCHEMBL7647791

SCHEMBL7647791

O=C(O)CCC(C(=O)O)C(c1cccc2ccccc12)[PH](=O)O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.42
HPGD P15428 2/20 0.42
CYP2C9 P11712 2/20 0.42
HTT P42858 1/20 0.42
TDP1 Q9NUW8 2/20 0.38
FOLH1 Q04609 1/20 0.38
ACP3 P15309 3/20 0.37
ALDH1A1 P00352 3/20 0.37
GAA P10253 1/20 0.36
CPA3 P15088 1/20 0.36
KDM4E B2RXH2 1/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2D6 P10635 2/20 0.35
SLC6A4 P31645 1/20 0.35
MC4R P32245 1/20 0.35
MC5R P33032 1/20 0.35
MC1R Q01726 1/20 0.35
METAP2 P50579 1/20 0.34
METAP1 P53582 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7647520 0.80 HDAC1 (0.35)
SCHEMBL7654118 0.79 HDAC3 (0.48) CYP2C19CYP2C9ALDH1A1GAAKDM4E
SCHEMBL6503232 0.77 CYP2C19 (0.50) CYP2C19HPGDCYP2C9HTTTDP1
SCHEMBL250818 0.76 CYP2C19 (0.49) CYP2C19HPGDCYP2C9HTTTDP1
SCHEMBL7647686 0.73 CCKBR (0.39) HPGDALDH1A1GAAKDM4E
SCHEMBL3134902 0.73 CYP2C19 (0.49) CYP2C19HPGDCYP2C9HTTTDP1
SCHEMBL7649464 0.72 PTPRA (0.39) CYP2C19HPGDALDH1A1GAACPA3
SCHEMBL5054750 0.72 ACP3 (0.39) CYP2C19HPGDCYP2C9HTTFOLH1
SCHEMBL729984 0.71 CYP2C19 (0.47) CYP2C19HPGDCYP2C9HTTTDP1
SCHEMBL27415339 0.71 CYP2C19 (0.47) CYP2C19HPGDCYP2C9HTTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2002514184-A 2002-05-14 JP claimed
EP-1005348-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 2000-06-07 EP claimed
WO-1998013046-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 1998-04-02 WO claimed